From the other side of the consultation, briefly.

NurseKim_ATL said:

...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

1. Document medical necessity (BMI, comorbidities, failed alternatives)
2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
4. Request peer-to-peer review between your doctor and the plan's medical director
5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

LabKate said:

Telehealth prescriber review for cost and coverage: I've used 3 different telehealth platforms to get my GLP-1 prescription.

Financial impact of cost and coverage weight loss beyond medication cost:

• Groceries: SAVED $251/month (eating less)
• Restaurants: SAVED $201/month (fewer meals out)
• Alcohol: SAVED $151/month (stopped drinking)
• Life insurance: Premium REDUCED by $41/month (lower BMI)
• Copays: SAVED $61/month (fewer BP/cholesterol meds)

Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.

Following on from LabKate — and this may be the naive question:

How long did you give it before you decided it was working?

bri_stats said:

Financial impact of cost and coverage weight loss beyond medication cost: Groceries: SAVED $251/month (eating less) Restaurants: SAVED $201/month…

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Moderator note: the sourcing question belongs in the vendor section and has been split out.